356 related articles for article (PubMed ID: 16316645)
1. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
[TBL] [Abstract][Full Text] [Related]
2. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
3. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
Mezzomo K; Cumming P; Minuzzi L
Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
7. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
9. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
11. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
[TBL] [Abstract][Full Text] [Related]
12. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
13. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
[TBL] [Abstract][Full Text] [Related]
14. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
[TBL] [Abstract][Full Text] [Related]
15. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activity of the histamine H3 receptor.
Arrang JM; Morisset S; Gbahou F
Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125
[TBL] [Abstract][Full Text] [Related]
17. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
18. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
[TBL] [Abstract][Full Text] [Related]
20. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.
Pan JB; Yao BB; Miller TR; Kroeger PE; Bennani YL; Komater VA; Esbenshade TA; Hancock AA; Decker MW; Fox GB
Life Sci; 2006 Aug; 79(14):1366-79. PubMed ID: 16730751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
